Lineage Cell Therapeutics, Inc. (LCTX): Total Liabilities
$69.24M
As of 2025-12-31
$46.42M
As of 2026-06-30
+10.2%
3-year compound annual growth
+40.1%
5-year compound annual growth
+14.3%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $69.24M | +91.2% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $36.21M | -7.2% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $39.00M | -24.6% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $51.73M | -38.2% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $83.65M | +552.4% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $12.82M | -9.9% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $14.23M | +51.2% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $9.41M | +4.9% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $8.98M | -25.6% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $12.06M | -33.8% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $18.21M | n/a | 2017-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
Compare LCTX, RLAY, PTHS, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗